Peptides / Sexual health and hormones

Small molecule · 406 Da

Enclomiphene

Not approvedBanned in sport

Enclomiphene is a form of clomiphene that acts on estrogen receptors, studied for low testosterone in men and not approved by the FDA or the EMA. Studies in people mostly measured sex hormones and fertility, and it is banned in sport. PepBank shows 43 results on enclomiphene from 7 studies in people, and 110 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Enclomiphene citrate, trans-Clomiphene, Enclomifene, Androxal, EnCyzix

Small molecule, shown without its saltPubChem 1548953

Evidence level: Some studies in people43 of 153 results come from studies in people.

Results in people

28% of 153 results

Results in animals

41% of 153 results

Results in lab cells

31% of 153 results

From computer models

0% of 153 results

Overview

Enclomiphene at a glance

What it is	Small molecule
Approval	Not approved for any use
In sport	Banned in sport (WADA S4.2)
Studies	48 studies with results. 46 of them gave enclomiphene, with 153 results. 43 in people63 in animals47 in lab cells
Best study in people	Randomized controlled trial with 7 people (2013)
Clinical trials	25 registered: 0 active or planned, 10 with posted results
Community use	Raising endogenous testosterone

The science

What is enclomiphene?

The E isomer of clomiphene and an estrogen receptor modulator studied for male hypogonadism. FDA did not approve it. EMA refused EnCyzix.

153

Study results in PepBank

The history of enclomiphene

1977
The oldest paper on enclomiphene in PepBank is from 1977.
2006March
A registered trial of enclomiphene started (NCT00962637).

Enclomiphene structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Enclomiphene is a small molecule, not a peptide chain.

Formula

C₂₆H₂₈ClNO

Molecular weight

406 g/mol

CAS number

15690-57-0

Target

Estrogen receptor: selective estrogen receptor modulatorEvidence: curated database or regulator description

Development

Repros Therapeutics (Androxal); Renable Pharma Limited (EnCyzix applicant). Highest phase: phase 3.

Identifiers

PubChem 1548953, ChEMBL CHEMBL954, UNII R6D2UI4FLS, DrugBank DB06735

SMILES and InChIKey

InChIKey
GKIRPKYJQBWNGO-OCEACIFDSA-N

SMILES
CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3

See charge, composition and 3D structure on the Scientific page

The evidence

What enclomiphene studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people43 of 153 results come from studies in people.

Sex hormones and fertility

89 results · 32 in people · 40 animal · 17 lab

In overweight hypogonadal men, FSH rose with enclomiphene and fell with testosterone gel. BJU international, 2016

Top results

In overweight hypogonadal men, FSH rose with enclomiphene and fell with testosterone gel. (BJU international, 2016)
In hypogonadal men, sperm counts rose in seven of seven men after three months of enclomiphene. (The journal of sexual medicine, 2013)
In hypogonadal men, testosterone averaged 525 ± 256 pg/dL after six months of enclomiphene. (The journal of sexual medicine, 2013)

Hormones

3 results · 3 in people

In hypogonadal men, ACTH did not significantly change with enclomiphene. BJU international, 2013

Top results

In hypogonadal men, ACTH did not significantly change with enclomiphene. (BJU international, 2013)
In hypogonadal men, TSH did not significantly change with enclomiphene. (BJU international, 2013)
In hypogonadal men, cortisol did not significantly change with enclomiphene. (BJU international, 2013)

Bones and joints

2 results · 1 in people · 1 animal

In hypogonadal men, bone markers did not significantly change with enclomiphene. BJU international, 2013

Top results

In hypogonadal men, bone markers did not significantly change with enclomiphene. (BJU international, 2013)
In zebrafish exposed at 5.5 mm SL, enclomiphene increased skull suture fusion compared with controls. (Plastic surgery, 2023)

Growth hormone and growth

2 results · 1 in people · 1 lab

In hypogonadal men, enclomiphene lowered IGF-1 more than testosterone gel. BJU international, 2013

Top results

In hypogonadal men, enclomiphene lowered IGF-1 more than testosterone gel. (BJU international, 2013)
In cells from rat pituitaries, enclomiphene increased growth hormone production after one week. (Endocrinology, 1977)

Cholesterol and blood fats

1 result · 1 in people

In hypogonadal men, blood lipids did not significantly change with enclomiphene. BJU international, 2013

Top results

In hypogonadal men, blood lipids did not significantly change with enclomiphene. (BJU international, 2013)

Cancer

7 results · 2 animal · 5 lab

In mice with EnCa101 tumors, enclomiphene stimulated tumor growth. Cancer research, 1990

Top results

In mice with EnCa101 tumors, enclomiphene stimulated tumor growth. (Cancer research, 1990)
In mice with human endometrial tumors, enclomiphene supported tumor growth as strongly as tamoxifen. (Annals of the New York Academy of Sciences, 1991)
In cells, low-dose enclomiphene inhibited breast cancer growth, but estradiol reversed this effect. (The Journal of clinical endocrinology and metabolism, 1983)

All 48 enclomiphene studies by area Open the Scientific page

Key enclomiphene studies

Studies in people come first, then studies in animals and in the lab.

People
Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel
Kaminetsky et al. 2013 · The journal of sexual medicine · 7 people · cited by 52
6 results
People
Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement
Kim et al. 2016 · BJU international · cited by 54
3 results
People
Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
Wiehle et al. 2014 · Fertility and sterility · cited by 49
5 results
People
Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics
Wiehle et al. 2013 · BJU international · cited by 31
14 results
People
Safety and efficacy of enclomiphene and clomiphene for hypogonadal men
Saffati et al. 2024 · Translational andrology and urology · 66 people · cited by 5
6 results

All 48 Enclomiphene studies

Enclomiphene clinical trials

ClinicalTrials.gov lists 25 trials of enclomiphene. 0 are active or planned, and 10 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Phase 3completed499 people

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Phase 3completed181 people

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Phase 3completed151 people

All 10 Enclomiphene trials

Status and safety

Is enclomiphene approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Refused

Refused.

WADA

Sport

Banned

On the 2026 Prohibited List, section S4.2.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026). Banned in sport (WADA S4.2).

Laws and labels change, so check the regulator for the current status.

Enclomiphene side effects and safety

PepBank has 18 safety results from studies of enclomiphene. 5 of them come from studies in people.

Safety results from studies (18)

In hypogonadal men, enclomiphene was linked to less frequent decreased libido than clomiphene. (Translational andrology and urology, 2024)
A man with prior heart surgery had atrial flutter detected after an enclomiphene dose increase. Causality was uncertain. (Cureus, 2026)
In hypogonadal men, enclomiphene was linked to less frequent reduced energy than clomiphene. (Translational andrology and urology, 2024)
In hypogonadal men, enclomiphene was linked to fewer mood changes than clomiphene. (Translational andrology and urology, 2024)
In hypogonadal men, enclomiphene was linked to lower odds of adverse events than clomiphene. (Translational andrology and urology, 2024)
In mice with human endometrial tumors, enclomiphene supported tumor growth as strongly as tamoxifen. (Annals of the New York Academy of Sciences, 1991)
In mice, isolated enclomiphene did not change testicular tissue structure. (BJU international, 2016)
In zebrafish exposed at 5.5 mm SL, enclomiphene increased skull suture fusion compared with controls. (Plastic surgery, 2023)
In mice, profound Leydig cell effects occurred only with zuclomiphene, rather than enclomiphene. (BJU international, 2016)
In mice, profound epididymal effects occurred only with zuclomiphene, rather than enclomiphene. (BJU international, 2016)
In mice, profound seminal vesicle effects occurred only with zuclomiphene, rather than enclomiphene. (BJU international, 2016)
In mice, profound kidney effects occurred only with zuclomiphene, rather than enclomiphene. (BJU international, 2016)
In lab tests with mouse oocytes, enclomiphene reduced fertilization rates as concentrations increased. (American journal of obstetrics and gynecology, 1986)
In lab tests with mouse embryos, enclomiphene reduced blastocyst formation rates as concentrations increased. (American journal of obstetrics and gynecology, 1986)
In lab tests with mouse embryos, enclomiphene increased degeneration rates as concentrations increased. (American journal of obstetrics and gynecology, 1986)
In lab tests with mouse oocytes, fertilization rates did not differ significantly between enclomiphene and zuclomiphene. (American journal of obstetrics and gynecology, 1986)
In lab tests with mouse embryos, blastocyst formation rates did not differ significantly between enclomiphene and zuclomiphene. (American journal of obstetrics and gynecology, 1986)
In lab tests with mouse embryos, degeneration rates did not differ significantly between enclomiphene and zuclomiphene. (American journal of obstetrics and gynecology, 1986)

See every safety result on the Scientific page

Doses studied (27 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
25 mg daily	Human	human	oral	six weeks	Randomized trial in people	Wiehle 2013
6.25, 12.5 and 25 mg	Human	human	oral	six weeks	Randomized trial in people	Wiehle 2013
50 mg daily instead of 25 mg daily	Human	human	Not reported	Not reported	Reports of single patients · n = 1	Tariq 2026
three implants each containing 150 mg	Animal	cow	silastic implants	d 20 to d 30 postpartum	Study in live animals · n = 52	Schramm 1991
30-cm implant	Animal	cow	subcutaneous implant	Implanted on d 20 and removed on d 29 postpartum	Study in live animals · n = 12	Chang 1987
10 mg	Animal	sheep	Not reported	Not reported	Study in live animals · n = 4	Gregg 1990
25 mg	Animal	sheep	Not reported	Not reported	Study in live animals · n = 4	Gregg 1990
100 mg	Animal	sheep	Not reported	Not reported	Study in live animals · n = 4	Gregg 1990
250 mg	Animal	sheep	Not reported	Not reported	Study in live animals · n = 4	Gregg 1990
100 micrograms every other day	Animal	mouse	subcutaneous	Four weeks	Study in live animals	Gottardis 1990
4 or 40 mg/kg/day	Animal	mouse	oral gavage	Not reported	Study in live animals	Fontenot 2016
500 micrograms per injection	Animal	rat	Not reported	Five daily injections	Study in live animals	Burghardt 1984
250 micrograms	Animal	rat	Not reported	5 days	Study in live animals	Burghardt 1984
.03 mg every 4 d	Animal	sheep	injection	Not reported	Study in live animals	Gregg 1990
.1 mg every 4 d	Animal	sheep	injection	Not reported	Study in live animals	Gregg 1990
1 mg every 4 d	Animal	sheep	injection	Not reported	Study in live animals	Gregg 1990
10 mg every 4 d	Animal	sheep	injection	Not reported	Study in live animals	Gregg 1990
.03, .1, 1 or 10 mg every 4 d	Animal	sheep	injection	Not reported	Study in live animals	Gregg 1990
0-500 microM	Lab	hamster	intrafollicular injection	6 or 10 h	Study on tissue taken from a body	Racowsky 1989
0.25-1.0 microM	Lab	human	Not reported	Not reported	Study on cells in a dish	Murphy 1983
>2.5 microM	Lab	human	Not reported	Not reported	Study on cells in a dish	Murphy 1983
About 10(-7) to 10(-6)M	Lab	rat	Not reported	one week	Study on cells in a dish	Dannies 1977
10(-6) M	Lab	sheep	Not reported	Not reported	Study on cells in a dish	Huang 1983
3-100 microM	Lab	ovine	Not reported	48-120 h	Study on cells in a dish	Opsahl 1996
820- to 900-fold molar excess above estradiol	Lab	calf	Not reported	Not reported	Test-tube study without cells	Sasson 1982
25 microM	Lab	human	Not reported	Not reported	Test-tube study without cells	Ghobadi 2008
100-fold excess competitor concentration	Lab	Nerodia	Not reported	Not reported	Test-tube study without cells	Riley 1988

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

One forum member reports enclomiphene use to raise testosterone, with a daily multivitamin as the only reported concurrent product. This report does not establish symptom benefits or safe long-term dosing.

Reported routines and cautions

What people use it for

Raising endogenous testosteroneS1

Reported regimens

Regimens that community sources report for Enclomiphene. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
One member report for low testosterone	oral	12.5 mg per dose	once daily	30 days	Single source. The source carries seller advertisements or affiliate links.	S1

Cautions

One member questions whether the purchased product is actually enclomiphene.S1

Community sources

S1Enclomiphene discussion, AnabolicMindsanabolicminds.comcarries seller links, not linked

Gaps

A forum report cannot verify product identity. The regimen author reports a concurrent multivitamin. Other doses appear in the thread but do not establish a standard regimen.

Questions and more

Ask a question about enclomiphene

The answer links to every study it uses.

What does the evidence say about enclomiphene?Is enclomiphene tested in people?Compare with Oxytocin Compare with Kisspeptin-10

Sources

Database: PepBank data for enclomiphene (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about enclomiphene

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Enclomiphene

Not approvedBanned in sport

Also known as Enclomiphene citrate, trans-Clomiphene, Enclomifene, Androxal, EnCyzix

What it is

Small molecule

Approval

Not approved for any use

In sport

Banned in sport (WADA S4.2)

Studies

48 studies with results. 46 of them gave enclomiphene, with 153 results.
43 in people63 in animals47 in lab cells

Best study in people

Randomized controlled trial with 7 people (2013)

Clinical trials

25 registered: 0 active or planned, 10 with posted results

Community use

Raising endogenous testosterone

Dose as reported

Class

Species

Route

Duration

Design

Source

25 mg daily

Human

human

oral

six weeks

Randomized trial in people

Wiehle 2013

6.25, 12.5 and 25 mg

Human

human

oral

six weeks

Randomized trial in people

Wiehle 2013

50 mg daily instead of 25 mg daily

Human

human

Not reported

Reports of single patients · n = 1

Tariq 2026

three implants each containing 150 mg

Animal

cow

silastic implants

d 20 to d 30 postpartum

Study in live animals · n = 52

Schramm 1991

30-cm implant

Animal

cow

subcutaneous implant

Implanted on d 20 and removed on d 29 postpartum

Study in live animals · n = 12

Chang 1987

10 mg

Animal

sheep

Not reported

Study in live animals · n = 4

Gregg 1990

25 mg

Animal

sheep

Not reported

Study in live animals · n = 4

Gregg 1990

100 mg

Animal

sheep

Not reported

Study in live animals · n = 4

Gregg 1990

250 mg

Animal

sheep

Not reported

Study in live animals · n = 4

Gregg 1990

100 micrograms every other day

Animal

mouse

subcutaneous

Four weeks

Study in live animals

Gottardis 1990

4 or 40 mg/kg/day

Animal

mouse

oral gavage

Not reported

Study in live animals

Fontenot 2016

500 micrograms per injection

Animal

rat

Not reported

Five daily injections

Study in live animals

Burghardt 1984

250 micrograms

Animal

rat

Not reported

5 days

Study in live animals

Burghardt 1984

.03 mg every 4 d

Animal

sheep

injection

Not reported

Study in live animals

Gregg 1990

.1 mg every 4 d

Animal

sheep

injection

Not reported

Study in live animals

Gregg 1990

1 mg every 4 d

Animal

sheep

injection

Not reported

Study in live animals

Gregg 1990

10 mg every 4 d

Animal

sheep

injection

Not reported

Study in live animals

Gregg 1990

.03, .1, 1 or 10 mg every 4 d

Animal

sheep

injection

Not reported

Study in live animals

Gregg 1990

0-500 microM

Lab

hamster

intrafollicular injection

6 or 10 h

Study on tissue taken from a body

Racowsky 1989

0.25-1.0 microM

Lab

human

Not reported

Study on cells in a dish

Murphy 1983

>2.5 microM

Lab

human

Not reported

Study on cells in a dish

Murphy 1983

About 10(-7) to 10(-6)M

Lab

rat

Not reported

one week

Study on cells in a dish

Dannies 1977

10(-6) M

Lab

sheep

Not reported

Study on cells in a dish

Huang 1983

3-100 microM

Lab

ovine

Not reported

48-120 h

Study on cells in a dish

Opsahl 1996

820- to 900-fold molar excess above estradiol

Lab

calf

Not reported

Test-tube study without cells

Sasson 1982

25 microM

Lab

human

Not reported

Test-tube study without cells

Ghobadi 2008

100-fold excess competitor concentration

Lab

Nerodia

Not reported

Test-tube study without cells

Riley 1988

Context

Route

Amount

How often

How long

Agreement

Sources

One member report for low testosterone

oral

12.5 mg per dose

once daily

30 days

Single source. The source carries seller advertisements or affiliate links.

Enclomiphene

Enclomiphene at a glance

What is enclomiphene?

The history of enclomiphene

Enclomiphene structure and chemistry

What enclomiphene studies show

Sex hormones and fertility

Hormones

Bones and joints

Growth hormone and growth

Cholesterol and blood fats

Cancer

Key enclomiphene studies

Enclomiphene clinical trials

Is enclomiphene approved?

Enclomiphene side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about enclomiphene

Related peptides

hCG vs enclomiphene

Sources

Enclomiphene

Enclomiphene at a glance

What is enclomiphene?

The history of enclomiphene

Enclomiphene structure and chemistry

What enclomiphene studies show

Sex hormones and fertility

Hormones

Bones and joints

Growth hormone and growth

Cholesterol and blood fats

Cancer

Key enclomiphene studies

Enclomiphene clinical trials

Is enclomiphene approved?

Enclomiphene side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about enclomiphene

Related peptides

hCG vs enclomiphene

Sources